A carregar...
GD2 or HER2 targeting T cell engaging bispecific antibodies to treat osteosarcoma
BACKGROUND: The cure rate for metastatic osteosarcoma has not substantially improved over the past decades. Clinical trials of anti-HER2 trastuzumab or anti-GD2 dinutuximab for metastatic or refractory osteosarcoma were not successful, and neither was immune checkpoint inhibitors (ICIs). METHODS: We...
Na minha lista:
| Publicado no: | J Hematol Oncol |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioMed Central
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7731630/ https://ncbi.nlm.nih.gov/pubmed/33303017 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-01012-y |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|